{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:20Z","timestamp":1793640560704,"version":"4.5.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novo Nordisk Inc.","id":[{"id":"https:\/\/ror.org\/0435rc536","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13300-026-01919-8","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:50:49Z","timestamp":1789631449000},"page":"1687-1701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type\u00a02 Diabetes and Atherosclerotic Cardiovascular Disease"],"prefix":"10.1007","volume":"17","author":[{"given":"Xi","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caichen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mico","family":"Guevarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-8597","authenticated-orcid":false,"given":"Adam","family":"de Havenon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"9","key":"1919_CR1","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","volume":"145","author":"JJ Joseph","year":"2022","unstructured":"Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type\u00a02 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722\u201359.","journal-title":"Circulation"},{"issue":"8","key":"1919_CR2","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2337\/dc08-0025","volume":"31","author":"CS Fox","year":"2008","unstructured":"Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D\u2019Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31(8):1582\u20134.","journal-title":"Diabetes Care"},{"issue":"6","key":"1919_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","volume":"113","author":"DM Lloyd-Jones","year":"2006","unstructured":"Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50\u00a0years of age. Circulation. 2006;113(6):791\u20138.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"1919_CR4","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179\u2013218.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1919_CR5","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular disease and risk management: standards of care in diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S216\u201345.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1919_CR6","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes.","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S183\u2013215.","journal-title":"Diabetes Care"},{"issue":"9","key":"1919_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type\u00a02 diabetes: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(9):1117\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1919_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13300-024-01678-4","volume":"16","author":"SE Inzucchi","year":"2025","unstructured":"Inzucchi SE, Tan X, Liang Y, Yedigarova L, Xie L, de Havenon A. Cardiovascular events in adults with type\u00a02 diabetes and ASCVD initiating once-weekly semaglutide vs DPP-4is in the USA. Diabetes Ther. 2025;16(2):187\u2013203.","journal-title":"Diabetes Ther"},{"key":"1919_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112473","volume":"229","author":"X Tan","year":"2025","unstructured":"Tan X, Harton J, Gutierrez C, et al. Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD. Diabetes Res Clin Pract. 2025;229:112473.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1919_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02051-8","volume":"22","author":"X Tan","year":"2023","unstructured":"Tan X, Liang Y, Rajpura JR, et al. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovasc Diabetol. 2023;22(1):319.","journal-title":"Cardiovasc Diabetol"},{"key":"1919_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112910","volume":"229","author":"SM Sklepinski","year":"2025","unstructured":"Sklepinski SM, Deng Y, Swarna KS, et al. Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type\u00a02 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025;229:112910.","journal-title":"Diabetes Res Clin Pract"},{"key":"1919_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2577762","author":"X Tan","year":"2025","unstructured":"Tan X, Liang Y, Xie L, et al. Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare advantage beneficiaries with T2D and ASCVD. Curr Med Res Opin. 2025. https:\/\/doi.org\/10.1080\/03007995.2025.2577762.","journal-title":"Curr Med Res Opin"},{"issue":"16 Suppl","key":"1919_CR13","first-page":"S325","volume":"26","author":"T Dougherty","year":"2020","unstructured":"Dougherty T, Heile M. Type\u00a02 diabetes in the US managed care setting: the burden of disease and rationale for an oral glucagon-like peptide-1 receptor agonist. Am J Manag Care. 2020;26(16 Suppl):S325\u201334.","journal-title":"Am J Manag Care"},{"issue":"1","key":"1919_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/dia.2019.0185","volume":"22","author":"JD Bucheit","year":"2020","unstructured":"Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol Ther. 2020;22(1):10\u20138.","journal-title":"Diabetes Technol Ther"},{"issue":"20","key":"1919_CR15","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type\u00a02 diabetes. N Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"key":"1919_CR16","unstructured":"Novo Nordisk. FDA approves Novo Nordisk\u2019s oral semaglutide for cardiovascular (CV) risk reduction in adults with type\u00a02 diabetes who are at high risk, including those who have not had a prior CV event 2025 (updated October 17, 2025). https:\/\/www.novonordisk-us.com\/media\/news-archive\/news-details.html?id=916435. Accessed 21 Oct 2025."},{"issue":"3","key":"1919_CR17","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/dom.70412","volume":"28","author":"K Cowart","year":"2026","unstructured":"Cowart K, Cornelio CK, Ansong B, Petrilli J, Carris NW. Association of oral semaglutide with cardiovascular outcomes in a real-world primary prevention population. Diabetes Obes Metab. 2026;28(3):2477\u201381.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1919_CR18","volume":"226","author":"S Mariscal Vazquez","year":"2026","unstructured":"Mariscal Vazquez S, Jimenez-Mendez C, Perez Asensio A, et al. Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk. Rev Clin Esp (Barc). 2026;226(6):502562.","journal-title":"Rev Clin Esp (Barc)"},{"key":"1919_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060856","author":"S Palazzi","year":"2025","unstructured":"Palazzi S, Sentinelli F, Zugaro A, et al. Real-world analysis of short-term effectiveness of oral semaglutide: impact on glycometabolic control and cardiovascular risk. Pharmaceuticals (Basel). 2025. https:\/\/doi.org\/10.3390\/ph18060856.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"1919_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","volume":"71","author":"KA Hicks","year":"2017","unstructured":"Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol. 2017;71(9):1021\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1919_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40264-018-0754-z","volume":"42","author":"S Singh","year":"2019","unstructured":"Singh S, Fouayzi H, Anzuoni K, et al. Diagnostic algorithms for cardiovascular death in administrative claims databases: a systematic review. Drug Saf. 2019;42(4):515\u201327.","journal-title":"Drug Saf"},{"issue":"5","key":"1919_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"1","key":"1919_CR23","first-page":"15","volume":"14","author":"BA Young","year":"2008","unstructured":"Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15\u201323.","journal-title":"Am J Manag Care"},{"issue":"30","key":"1919_CR24","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35(30):5642\u201355.","journal-title":"Stat Med"},{"issue":"22","key":"1919_CR25","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1002\/sim.9519","volume":"41","author":"PC Austin","year":"2022","unstructured":"Austin PC. Bootstrap vs asymptotic variance estimation when using propensity score weighting with continuous and binary outcomes. Stat Med. 2022;41(22):4426\u201343.","journal-title":"Stat Med"},{"issue":"24","key":"1919_CR26","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1002\/sim.6276","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC, Small DS. The use of bootstrapping when using propensity-score matching without replacement: a simulation study. Stat Med. 2014;33(24):4306\u201319.","journal-title":"Stat Med"},{"issue":"3","key":"1919_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383\u20138.","journal-title":"Epidemiology"},{"issue":"5","key":"1919_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322606","volume":"20","author":"X Chen","year":"1990","unstructured":"Chen X, Lu L, Xiao C, et al. Global burden of ischemic stroke in adults aged 60\u00a0years and older from 1990 to 2021: population-based study. PLoS ONE. 1990;20(5):e0322606.","journal-title":"PLoS ONE"},{"issue":"5","key":"1919_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","volume":"23","author":"VR Aroda","year":"2022","unstructured":"Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type\u00a02 diabetes. Rev Endocr Metab Disord. 2022;23(5):979\u201394.","journal-title":"Rev Endocr Metab Disord"},{"issue":"15","key":"1919_CR30","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type\u00a02 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"9","key":"1919_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","volume":"11","author":"R Adhikari","year":"2022","unstructured":"Adhikari R, Jha K, Dardari Z, et al. National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11(9):e023811.","journal-title":"J Am Heart Assoc"},{"key":"1919_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.03.017","volume":"224","author":"Y Gao","year":"2020","unstructured":"Gao Y, Peterson E, Pagidipati N. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. Am Heart J. 2020;224:47\u201353.","journal-title":"Am Heart J"},{"issue":"1","key":"1919_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","volume":"144","author":"AJ Nelson","year":"2021","unstructured":"Nelson AJ, Pagidipati NJ, Aroda VR, et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation. 2021;144(1):74\u201384.","journal-title":"Circulation"},{"issue":"24","key":"1919_CR34","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hernan","year":"2022","unstructured":"Hernan MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328(24):2446\u20137.","journal-title":"JAMA"},{"key":"1919_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.07.007","author":"VW Dayer","year":"2025","unstructured":"Dayer VW, Nourhussein I, Kasle A, Hansen RN, Navas A, Sullivan SD. Comprehensive access to semaglutide: clinical and economic implications for Medicare. Value Health. 2025. https:\/\/doi.org\/10.1016\/j.jval.2025.07.007.","journal-title":"Value Health"},{"key":"1919_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156463","volume":"175","author":"P Karakasis","year":"2026","unstructured":"Karakasis P, Vlachos K, Antoniadis AP, et al. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2026;175:156463.","journal-title":"Metabolism"},{"key":"1919_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112452","volume":"228","author":"C Sardu","year":"2025","unstructured":"Sardu C, Marfella LV, Rinaldi L, et al. Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type\u00a02 diabetes mellitus patients receiving chronic anti-diabetic medications: a multicenter observational study. Diabetes Res Clin Pract. 2025;228:112452.","journal-title":"Diabetes Res Clin Pract"},{"key":"1919_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199285","author":"C Sardu","year":"2025","unstructured":"Sardu C, Marfella R. Effects of combined therapy with SGLT2i and GLP-1RAs on atrial fibrillation recurrence after catheter ablation in diabetic cohorts: one-year outcomes from continuous monitoring. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26199285.","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1919_CR39","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","volume":"151","author":"N Marx","year":"2025","unstructured":"Marx N, Deanfield JE, Mann JFE, et al. Oral semaglutide and cardiovascular outcomes in people with type\u00a02 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation. 2025;151(23):1639\u201350.","journal-title":"Circulation"},{"issue":"1","key":"1919_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02118-6","volume":"23","author":"R Marfella","year":"2024","unstructured":"Marfella R, Prattichizzo F, Sardu C, et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type\u00a02 diabetes. Cardiovasc Diabetol. 2024;23(1):10.","journal-title":"Cardiovasc Diabetol"},{"key":"1919_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024;385:e078242.","journal-title":"BMJ"},{"issue":"1","key":"1919_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01635-6","volume":"17","author":"A Mousavi","year":"2025","unstructured":"Mousavi A, Shojaei S, Soleimani H, et al. Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17(1):68.","journal-title":"Diabetol Metab Syndr"},{"key":"1919_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-026-03239-4","author":"E Stamouli","year":"2026","unstructured":"Stamouli E, Trakatelli CM, Sarigianni M, Kitsios K, Kotsis V. Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review. Cardiovasc Diabetol. 2026. https:\/\/doi.org\/10.1186\/s12933-026-03239-4.","journal-title":"Cardiovasc Diabetol"},{"key":"1919_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112595","author":"N Homorodi","year":"2025","unstructured":"Homorodi N, Varga E, Szabo Z, Sztanek F, Harangi M. Complementary yet distinct roles of GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular risk reduction. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13112595.","journal-title":"Biomedicines"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01919-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:35Z","timestamp":1793638955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01919-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1919"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01919-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xi Tan, Yuanjie Liang, Caichen Zhong, Lin Xie, Mico Guevarra, and Caroline Swift are employees of Novo Nordisk Inc. Adam de Havenon reports NIH\/NINDS funding, investigator-initiated clinical research funding from AAN, consultant fees from Novo Nordisk, royalty fees from UpToDate, and equity in Titin KM and Certus.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. This study involved retrospectively collected deidentified data, which was analyzed without interaction with the human subjects or reidentifying subjects. It was deemed to be exempt from institutional review board (IRB) review as determined by WCG IRB was exempt under 45\u00a0CFR\u00a0\u00a7 46.104(d)(4). This study analyzed secondary data from Optum\u2019s deidentified CDM Database data without direct subject contact or intervention; per 45\u00a0CFR\u00a046, analyses of secondary, deidentified data are not human subjects research and do not require consent.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}